← Eichor
Condition: Carcinoma Merkel Cell Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Carcinoma Merkel Cell

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Personalised Immunotherapy Platform
Phase N/A · 3 location(s) · Melanoma Institute Australia · NCT06536257Validation of in Vitro Method for Anti-MCPyV Immunotherapy on Patients With Cutaneous Merkel Cell Carcinoma
Phase N/A · 1 location(s) · Assistance Publique - Hôpitaux de Paris · NCT06780475At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Phase 2 · 2 location(s) · Mayo Clinic · NCT05969860Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
Phase 1/Phase 2 · 2 location(s) · University of Arizona · NCT06814496IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC)
Phase 1 · 2 location(s) · TuHURA Biosciences, Inc. · NCT06940440Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors
Phase 1 · 20 location(s) · SystImmune Inc. · NCT07080242A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
Phase 1 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT05859074The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Tr
Phase 2 · 1 location(s) · Mayo Clinic · NCT07285044Neoadjuvant PD-1 Blockade in Resectable Merkel Cell Carcinoma
Phase 2 · 1 location(s) · Abramson Cancer Center at Penn Medicine · NCT05496036Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metasta
Phase 1/Phase 2 · 26 location(s) · National Cancer Institute (NCI) · NCT05896839MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
Phase 1 · 2 location(s) · Memgen, Inc. · NCT05076760Studying Off Label Insurance Coverage for Patients With Cutaneous Cancers a "Filter" Observational Study
Phase N/A · 1 location(s) · Ohio State University Comprehensive Cancer Center · NCT07215988Electrochemotherapy (ECT) in Patients With Primary Visceral Tumors and/or Secondary Visceral Localizations, of Any Histo
NA · 1 location(s) · Istituto Oncologico Veneto IRCCS · NCT06753136Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT02479698A Study of VET3-TGI in Patients With Solid Tumors
Phase 1 · 7 location(s) · KaliVir Immunotherapeutics · NCT06444815A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participan
Phase 1/Phase 2 · 7 location(s) · Merck Sharp & Dohme LLC · NCT07302347A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Phase 1/Phase 2 · 13 location(s) · AstraZeneca · NCT07115043Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Phase 1/Phase 2 · 7 location(s) · Neonc Technologies, Inc. · NCT06047379Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Loc
Phase 1/Phase 2 · 18 location(s) · Aulos Bioscience, Inc. · NCT05267626A Beta-only IL-2 ImmunoTherapY Study
Phase 1/Phase 2 · 27 location(s) · Medicenna Therapeutics, Inc. · NCT05086692A Study of CRD3874-SI in People With Solid Tumors
Phase 1 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT06021626TIL Therapy in cSCC and MCC
Phase 2 · 1 location(s) · Karam Khaddour, MD, MS · NCT07288073Sentinel Lymph Node Biopsy in Ocular Surface and Adnexal Cancers
Phase N/A · 1 location(s) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · NCT05797415Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced
Phase 2/Phase 3 · 18 location(s) · TuHURA Biosciences, Inc. · NCT06947928Neoadjuvant Merkel Cell Carcinoma Therapy (Tx) With the PD-1 Inhibitor Cemiplimab
Phase 2 · 14 location(s) · Institut für Klinische Krebsforschung IKF GmbH at Krankenhau · NCT07387198Hypofractionated Radiation Therapy for Merkel Cell Carcinoma
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT05100095A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants W
Phase 1/Phase 2 · 32 location(s) · Marengo Therapeutics, Inc. · NCT05592626Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Mayo Clinic · NCT05269381French National Database of Rare Dermatological Cancers
Phase N/A · 34 location(s) · University Hospital, Lille · NCT03210935A First-in-Human Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of KUP-101A in Patients With Select
Phase 1 · 2 location(s) · Kupando GmbH · NCT07600476
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.